Zenas BioPharma
Zenas BioPharma is seeking a Senior Director, Commercial Systems, to lead the development and execution of the company's commercial IT strategy in preparation for a product launch and ongoing operations. The role involves overseeing the selection, implementation, and management of commercial technology platforms, data management, and analytics to support sales, marketing, medical affairs, and market access functions.
Zenas BioPharma is a biotechnology company focused on discovering and developing therapies for autoimmune and inflammatory diseases. Their stated mission is “Enabling patients with autoimmune diseases to reimagine life,” and they concentrate on finding I&I (inflammation & immunology) innovations. Zenas advances novel drug candidates through discovery and development with the goal of bringing new treatment options to patients and partnering across the biopharma ecosystem.
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings
1 day ago
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 weeks ago
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
Jan 5, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Zenas BioPharma.
81% above the average for this role
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4
3 weeks ago
Director, Commercial Operations-East
Jobgether
Senior Manager, Commercial and Medical Systems
Genetix Biotherapeutics
Director, Commercial Technology
BeOne Medicines
Veeva PromoMats and Commercial Platforms Solution Architect (Contractor)
Cristcot
Associate Director, Commercial Data & Business Systems
CG Oncology
Sr Commercial Data Analyst
Mundipharma